cinnarizine and Stroke

The study aimed at the evaluation of clinical efficacy and safety of the neurotrophic medication omaron, a combination of piracetam and cinnarizin, in the early restoration period of ischemic stroke. One hundred and twenty post stroke patients were examined. A diagnosis was confirmed by the brain MRI and CT examination. Neurological and mental status of patients was assessed with a number of scales. The omaron therapy reduced significantly the neurological deficit and improved health status and functioning of patients. The drug was well-tolerated by patients.

Topics: Calcium Channel Blockers; Cinnarizine; Drug Combinations; Humans; Neuroprotective Agents; Piracetam; Stroke; Stroke Rehabilitation

Efficacy of omaron (a combination of piracetam 400 mg and cinnarizin 25 mg) has been studied 3 months after stroke in 90 post-stroke patients. Forty-five patients receiving the basic therapy (antihypertensive and antithrombotic drugs, statins) have been included in the control group and 45 patients of the main group received in addition omaron (1 pill 3 times daily during 2 months). Intensity of neurologic disturbances, degree of disability, cognitive functions assessed by neuropsychological tests (the Mini-Mental State Examination, the Frontal Assessment battery, the Five words test, the Clock drawing test, the Schulte test) and emotional state (the Centre for Epidemiologic Studies Depression scale, the Spilberger scale) have been measured. During the period of the study, none of the patients had stroke or myocardial infarction. The improvement of indices of neurological status, decrease of disability degree and normalization of arterial pressure were found in both groups after 2 months of treatment. The significant improvement (p<0,05) of performance on tests for neurocognitive functions and parameters of emotional state was noted in patients treated with omaron compared to those of the control group. The good tolerability of omaron, absence of serious side-effect in combination with other drugs used for prevention of secondary stroke were reported.

Topics: Administration, Oral; Aged; Cinnarizine; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Histamine H1 Antagonists; Humans; Male; Middle Aged; Neuroprotective Agents; Piracetam; Stroke; Treatment Outcome